接受阿那曲唑治疗的乳腺癌女性中Wnt抑制剂、骨密度与生活方式参数的关联
Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy.
作者信息
Bojanić Kristina, Bilić Ćurčić Ines, Kuna Lucija, Kizivat Tomislav, Smolic Robert, Raguž Lučić Nikola, Kralik Kristina, Šerić Vatroslav, Ivanac Gordana, Tucak-Zorić Sandra, Včev Aleksandar, Smolić Martina
机构信息
Department of Mineral Metabolism, Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek 31000, Croatia.
Department of Radiology, Health Center Osijek, Osijek31000, Croatia.
出版信息
J Clin Med. 2018 Sep 17;7(9):287. doi: 10.3390/jcm7090287.
AIM
To determine the levels of Wnt inhibitors in patients treated with aromatase inhibitors (AIs) prior to therapy and to investigate their association with bone mineral density (BMD) and lifestyle parameters.
METHODS
137 breast cancer patients were divided into a group treated with 1 mg of anastrozole and a group w/o anastrozole therapy. Serum concentrations of sclerostin and dickkopf1 (DKK1) were measured by ELISA. BMD was measured by dual-energy X-ray absorptiometry (DXA). Lifestyle factors were investigated by a self-reported questionnaire.
RESULTS
Sclerostin was significantly higher in the AI-treated group (31.8 pmol/L vs. 24.1 pmol/L; < 0.001), whereas DKK1 was significantly lower in the AI-treated group (24.3 pmol/L vs. 26.02 pmol/L; < 0.001). Total hip and femoral neck BMD were significantly lower in the AI-treated group.
CONCLUSION
AI treatment was associated with increased levels of sclerostin and decreased levels of DKK1.
目的
确定在接受芳香化酶抑制剂（AI）治疗前患者体内Wnt抑制剂的水平，并研究其与骨密度（BMD）及生活方式参数之间的关联。
方法
137例乳腺癌患者被分为接受1mg阿那曲唑治疗的组和未接受阿那曲唑治疗的组。通过酶联免疫吸附测定法（ELISA）测量血清中硬化蛋白和Dickkopf1（DKK1）的浓度。采用双能X线吸收法（DXA）测量骨密度。通过自我报告问卷对生活方式因素进行调查。
结果
接受AI治疗的组中硬化蛋白水平显著更高（31.8皮摩尔/升对24.1皮摩尔/升；P<0.001），而接受AI治疗的组中DKK1水平显著更低（24.3皮摩尔/升对26.02皮摩尔/升；P<0.001）。接受AI治疗的组中全髋和股骨颈骨密度显著更低。
结论
AI治疗与硬化蛋白水平升高及DKK1水平降低相关。
Zotero 插件